The cancer-immunity cycle: Indication, genotype, and immunotype

I Mellman, DS Chen, T Powles, SJ Turley - Immunity, 2023 - cell.com
The cancer-immunity cycle provides a framework to understand the series of events that
generate anti-cancer immune responses. It emphasizes the iterative nature of the response …

Breaking the stromal barrier in pancreatic cancer: Advances and challenges

M Chakkera, JB Foote, B Farran… - Biochimica et Biophysica …, 2024 - Elsevier
Pancreatic cancer (PC) remains a leading cause of mortality worldwide due to the absence
of early detection methods and the low success rates of traditional therapeutic strategies …

[HTML][HTML] Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity

X Liu, GD Hogg, C Zuo, NC Borcherding, JM Baer… - Cancer Cell, 2023 - cell.com
Chronic activation of inflammatory pathways and suppressed interferon are hallmarks of
immunosuppressive tumors. Previous studies have shown that CD11b integrin agonists …

Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy

X Liu, JM Baer, ML Stone, BL Knolhoff… - Science translational …, 2024 - science.org
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy that is often resistant to
therapy. An immune suppressive tumor microenvironment (TME) and oncogenic mutations …

Good CARMA: Turning bad tumor‐resident myeloid cells good with chimeric antigen receptor macrophages

CM Snyder, SI Gill - Immunological Reviews, 2023 - Wiley Online Library
In religious philosophy, the concept of karma represents the effect of one's past and present
actions on one's future. Macrophages are highly plastic cells with myriad roles in health and …

Pancreatic ductal adenocarcinoma cells reshape the immune microenvironment: Molecular mechanisms and therapeutic targets

Y Zhao, C Qin, C Lin, Z Li, B Zhao, T Li, X Zhang… - … et Biophysica Acta (BBA …, 2024 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is a digestive system malignancy characterized
by challenging early detection, limited treatment alternatives, and generally poor prognosis …

An integrated overview of the immunosuppression features in the tumor microenvironment of pancreatic cancer

J Guo, S Wang, Q Gao - Frontiers in Immunology, 2023 - frontiersin.org
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies. It is
characterized by a complex and immunosuppressive tumor microenvironment (TME), which …

Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma

A Shah, K Ganguly, S Rauth, SS Sheree, I Khan… - Drug Resistance …, 2024 - Elsevier
Despite the ongoing advances in interventional strategies (surgery, chemotherapy,
radiotherapy, and immunotherapy) for managing pancreatic ductal adenocarcinoma …

[HTML][HTML] Organoids, tissue slices and organotypic cultures: advancing our understanding of pancreatic ductal adenocarcinoma through in vitro and ex vivo models

SA Aksoy, J Earl, J Grahovac, D Karakas… - Seminars in Cancer …, 2024 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses of all common
solid cancers. For the large majority of PDAC patients, only systemic therapies with very …

Steering Piezocatalytic Therapy for Optimized Tumoricidal Effect

H Zheng, H Lin, H Tian, K Lin, F Yang… - Advanced Functional …, 2024 - Wiley Online Library
Piezocatalysts, because of their mechano‐electrical conversion properties, are exploited for
various medical applications, such as sterilization, tissue engineering, biosensing, and …